Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
about
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseasePharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.Parkinson Disease and Dementia.Cognitive decline and quality of life in incident Parkinson's disease: The role of attentionPrevalence and Subtypes of Mild Cognitive Impairment in Parkinson's Disease.Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease.Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.Advances in the treatment of cognitive impairment in Parkinson's disease.Therapy-resistant symptoms in Parkinson's disease.Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Cognitive decline in Parkinson disease.Neuropsychiatric Issues in Parkinson's Disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Current and experimental treatments of Parkinson disease: A guide for neuroscientists.Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation.Integrating Patient Concerns into Parkinson's Disease Management.Validation of a Behavioral Approach for Measuring Saccades in Parkinson's Disease.Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.Nonmotor Symptoms of Parkinson's Disease.Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.Mild Cognitive Impairment in Parkinson's Disease-What Is It?
P2860
Q26745661-B50D887A-C9F7-460C-B6CA-7CD9FF59EAB3Q30244035-1EC8F80F-E5C6-421A-9458-E114AB4B4D7CQ30248574-F8DB254C-7471-406C-AEBB-11DFF3BF29D0Q37000056-ACFBC6BE-4788-498B-A457-0145ECCE6AF8Q37271669-D4D9FEA8-FF69-4F28-8632-B149994A903DQ37682538-4B4D2F17-38E7-488C-AE7A-AEAD0A527550Q38556646-E38DAF43-B204-4B78-BDCD-656A257AB72EQ38571668-82B27FAB-8462-479D-BF55-6DB3DF9CEB8CQ38593798-FDF615E2-1D5B-4B00-B249-AF54E001DF8BQ38661735-F1CEDDCE-91F9-48F1-9ED7-EB935A0CB334Q38751099-47D2CD1C-8EB3-4FF3-91E9-CBA770A7DD41Q38799051-03CD3CDD-6EFE-4648-AD20-5E196CA0D816Q38845546-15CCBB38-E106-47D2-ABDF-EE82F0FDBBA1Q38941557-1C0A2585-5FFF-4626-BF85-DAE1E170E9BCQ38964782-6AA97F2E-DC09-40B0-BC71-0A26C69E5527Q39094808-6E2FCCBD-1631-4D0A-9F01-E66FB620F1EDQ48575402-F26BB30A-1DB9-4556-A6D3-62D37DEC8B05Q48834526-9D01434A-3F14-49F9-B578-AAC98942B3C4Q53887877-B200ED95-D306-4228-B51F-9335A67502DDQ54975082-FA512864-EA64-4D31-8A7B-A09985761E76Q55387790-8549C85C-CB0B-4DF7-AAF7-D1B2E30B38E7
P2860
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@en
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@nl
type
label
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@en
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@nl
prefLabel
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@en
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@nl
P2093
P2860
P356
P1433
P1476
Rivastigmine for mild cognitiv ...... e: a placebo-controlled study.
@en
P2093
Emilie Melvin
Eugenia Mamikonyan
Sharon X Xie
P2860
P304
P356
10.1002/MDS.26236
P407
P577
2015-04-25T00:00:00Z